Inventurus Knowledge Solutions Limited — Q3 FY25 earnings call

Call held 6 Feb 2025

Management summary

Inventurus Knowledge Solutions (IKS) reported strong Q3 FY25 results, with revenue growing 16% YoY to ₹657.2 crores and EBITDA margin expanding to nearly 31%. The company secured significant deals, including a 15-year contract with Palomar Health and a JV with Radiology Partners, while also launching its GenAI-powered Scribble Now suite. Despite strategic customer base optimization and AQuity integration-related revenue dampening, IKS demonstrated robust growth and margin expansion, driven by accelerated cross-sell and operational efficiencies.

Highlights

  • Revenue grew 16% YoY to ₹657.2 crores, exceeding the 12% outsourced TAM growth rate.

  • Consolidated EBITDA margin expanded significantly by 650 bps YoY to nearly 31%, ahead of the projected glide path.

  • Headcount decreased by 100 people to 13,150, demonstrating operational efficiency and non-linearity in growth.

  • Secured a 15-year, full platform deal with Palomar Health, including a $16.5 million upfront guarantee and gain-share mechanism.

  • Formed a strategic JV with Radiology Partners, targeting $600-700 million/year in value creation through a virtual radiology assistant model.

Concerns

  • Revenue growth experienced a dampening effect due to strategic reduction of smaller AQuity customers (from 850+ to ~750) and offering discounts for model transformation.

  • Reported IPO-related expenses of ₹25 crores, although these were non-recurring and recovered in January.

Key financials

  1. Revenue ₹657.2 Cr +16%YoY
  2. EBITDA ₹201 Cr +24%YoY
  3. EBITDA Margin 30.5%
  4. Adjusted EBITDA ₹207 Cr
  5. PAT ₹130 Cr +28%YoY
  6. EPS ₹8
  7. ROE 33.2%
  8. Operating Cash Flow ₹154 Cr
  9. Free Cash Flow ₹109.5 Cr
  10. Headcount 13,150 employees -0.75%YoY

What they filed

Q1 FY27: revenue up 48.9%, net profit up 44.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue240 241 290 319 356 +48%404 +68%413 +42%475 +49%
EBITDA116 103 129 150 178 +53%196 +90%212 +64%219 +46%
Net profit92 83 100 113 138 +50%146 +76%169 +69%163 +44%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Order book

medium confidence

Pipeline

deal pipeline tcv

IKS is targeting 500-odd large enterprise customers, employing 150,000 physicians (18% of US market), for full platform cross-sell, representing a massive growth runway.

The company has seen faster-than-anticipated cross-sell activation, leading to robust revenue growth despite strategic customer base optimization.

Source: Prepared remarks

Capital allocation

high confidence
  • Debt Net ₹503 Cr
    • Repayment Net debt reduced from ₹850 crores in FY24 to ₹503 crores (business as usual) by Q3 FY25 due to strong cash generation. ₹347 Cr
    So, if you remember, in FY '24 our net debt position was Rs.850 crores. Through very healthy cash generation, we were able to pare it down to Rs.553 crores by the first half. And business as usual, this cash generation that we had done would have brought down our net debt position to Rs. 503 crores.
  • M&A AQuity Inc. Acquisition · Integrated

    Expanded customer base to north of 850-odd customers, with 500-odd being enterprise scale consolidator customers, and to transition from human-led to tech-led operating model.

    Blended margins dropped from 24% pro forma after AQuity's consolidation into IKS, with a target to return to early to mid-30s steady state.

    But through the acquisition of AQuity Inc., we expanded that customer base to north of 850-odd customers, of which really 500-odd tend to be that enterprise scale consolidator customers. ... transform the AQuity operating model with the IKS operating model. And in that process, take our blended margins that had dropped from 24% pro forma after AQuity's consolidation into IKS back towards that early to mid-30s which we think is where the steady state business should settle down at.
  • Liquidity Liquidity disclosed Strong cash generation enabled significant debt paydown and reduced interest expense.
    Our finance cost, I already mentioned that we have been already able to pare down our debt fairly significantly, which is why you see that number is coming down and it will continue to come down in the future as well.

Guidance & targets

Profitability

  • Consolidated EBITDA Margin Profitability · next 18 to 24 months · Medium confidence early to mid-30s
    we had mentioned that we believe we will get to the early to mid-30s consolidated EBITDA margins perhaps over the next 18 to 24 months.

    — Sachin Gupta

Revenue

  • Revenue Growth Revenue · over a period of time · Medium confidence well north of 12%
    over a period of time, we believe that our growth will continue to be well north of that 12% that the outsourced TAM is growing at.

    — Sachin Gupta

  • Revenue Growth Revenue · next several years · High confidence faster than 12% to 16% YoY
    we have any reason to slow down that growth to any lower than much faster than the 12%. So, that's one. Yes, we will continue to optimize margins. We have been a little lucky in that we have been able to accelerate that faster than what we had originally thought. And I think as long as we stay on that path, maybe we get to the steady-state margins towards the mid-30s instead of the next two years within a year. So, yes, I do believe that we will be able to deliver significantly faster than the 12% growth and continue to run towards that steady-state EBITDA margin profile of getting to the mid-30s over the next year.

    — Sachin Gupta

Product Development

  • New Features Launch Product Development · next 12 to 18 months · Medium confidence 3-4 new features
    I would not be surprised if we would reveal three to four new features over the next 12 to 18 months.

    — Sachin Gupta

Debt

  • Debt-Free Status Debt · sometime next fiscal · Medium confidence debt free
    So, all things remaining equal, remember, we have operated for 16 years with no debt and actually significant amount of cash. So, all things remaining equal, we should be able to get debt free sometime next fiscal.

    — Sachin Gupta

What to watch in Q4 FY25

Debt-Free Status

next fiscal (FY26)
Current Net debt of ₹503 crores
Target Debt-free

Why it matters

Achieving debt-free status will improve financial flexibility and reduce finance costs, boosting profitability.

So, all things remaining equal, remember, we have operated for 16 years with no debt and actually significant amount of cash. So, all things remaining equal, we should be able to get debt free sometime next fiscal.

Risks & concerns

  • Revenue growth dampening from AQuity integration

    medium

    Strategic reduction of smaller AQuity customers and discounts for model transformation had a dampening effect on Q3 revenue growth.

    Management acknowledged

  • Seasonality in Q3 and Q4

    low

    Q3 and Q4 are traditionally weaker quarters due to holiday season and winter weather, making YoY comparisons more relevant.

    Management acknowledged

  • Competitive environment in RCM market

    low

    The RCM market is intensely competitive, with various models converging towards tech-driven solutions, but IKS believes its full platform approach is a differentiator.

    Management acknowledged

Q&A highlights

6 direct
AQuity cross-selling traction and ramp-up Direct
But happy to note that in Q3 itself we were able to start to see traction in the cross-sell motion. There are several deals that we were able to consummate in Q3. The one that I am able to publicly announce is the Louisiana Children's Medical Center, which is a very significant health system in the New Orleans area.

Reveals that cross-sell, a key strategic pillar, is gaining traction faster than anticipated, contributing to current growth.

Asked by Seema Nayak

Breakdown of revenue growth between heritage IKS and AQuity Partial
While we do not want to give specific numbers because we really are now operating like one company and one platform, I will tell you that the growth in the legacy IKS business has been robust. Also, there's been some tremendous new logo addition, like I called out in deals like Palomar and Western Washington and Radiology Partners, which are all reflecting in the IKS numbers.

Clarifies that heritage IKS is growing robustly, offsetting dampening effects from AQuity, but avoids specific numerical breakdown.

Asked by Abhishek Kumar

Palomar deal structure and financial impact Direct
the first $16.5 million of the net economic value add that will be created will come to IKS. After that, up to a certain threshold, the net economic value add is shared 50-50 between IKS and Palomar, and then another certain threshold, a larger amount of the benefit accrues to Palomar.

Details the unique gain-share model of the 15-year Palomar deal, highlighting non-linear margin potential for IKS.

Asked by Abhishek Kumar

Future M&A strategy post-AQuity Direct
Our inorganic strategy will be much more focused on perhaps bleeding-edge technology-type acquisitions, where we will be able to bring the power of our massive customer base and the access to data and context that we have, by which we can mature that technology rapidly.

Outlines a clear shift in M&A focus towards tuck-in tech acquisitions to enhance platform capabilities rather than large-scale customer base expansion.

Asked by Gaurav

AQuity margin transformation progress and runway Direct
we have gotten to nearly a 31% EBITDA margin and a 32-odd percent adjusted EBITDA margin in this quarter itself. But I think you can safely assume that the AQuity margins are well on their way to transformation and there is still a significant runway ahead of us.

Confirms significant progress in AQuity's margin improvement, indicating the integration strategy is yielding results faster than expected.

Asked by Nilesh Jain

Debt-free timeline and capital allocation priorities Partial
So, all things remaining equal, remember, we have operated for 16 years with no debt and actually significant amount of cash. So, all things remaining equal, we should be able to get debt free sometime next fiscal. But obviously, there might be other uses of capital, including tuck-in tech acquisitions, more innovative arrangements with customers where we align the value that we create with their outcomes.

Provides a timeline for becoming debt-free but also highlights potential alternative uses of capital that could delay this, indicating strategic flexibility.

Asked by Siddharth Mishra

Aggressiveness in cutting AQuity clients vs. overall growth Direct
So, I have maintained through the roadshows, and I will still maintain that the opportunity that we have created for ourselves is to execute far faster than the 12% TAM growth over the next 10, 15 years, not just over the next few quarters. So, I have no reason to believe going into Q4 and well into the next several years, we have any reason to slow down that growth to any lower than much faster than the 12%.

Reassures that strategic client rationalization will not impede overall growth, which is expected to remain significantly above market TAM growth.

Asked by Siddharth Mishra

Continuum of care for patients and India market opportunity Direct
our entire offering that enables total cost of care management in fully delegated risk contracts actually involves exactly that, where we are building care coordination, transition of care management models, enabling effective home-based care for patients, community-based care enablement, all of that is really aimed at managing the patient across their journey within the continuum of care, including their home.

Highlights IKS's strategic expansion into comprehensive continuum of care management, addressing a critical need in healthcare beyond traditional RCM.

Asked by Hemendra Kumar

3 min read 7 chapters

Detailed narrative

Strategic Vision and Market Opportunity

IKS operates as a Care Enablement Platform in the US healthcare physician segment, a $1.5 trillion market within the $5 trillion US healthcare industry. Physicians spend 15% of their revenue, or $225 billion, on non-patient care tasks, representing a total addressable market (TAM) growing at 8%. The outsourced TAM, currently $30 billion, is growing at 12%, indicating significant opportunity for IKS's tech-led human-in-the-loop platform, which addresses 16 distinct chore tasks.

Q3 FY25 Financial Performance

For Q3 FY25, IKS reported a robust revenue of ₹657.2 crores, marking a 16% year-on-year growth. Consolidated EBITDA margin expanded significantly by 650 basis points to nearly 31%, with EBITDA reaching ₹201 crores (24% YoY growth). Profit After Tax (PAT) grew 28% YoY to ₹130 crores, and Adjusted PAT (excluding amortization) grew 31% YoY to ₹145 crores, demonstrating strong profitability and operational leverage.

AQuity Integration and Customer Base Optimization

The company is actively integrating the AQuity acquisition, which expanded its customer base to over 850, with a focus on retaining 500-odd large enterprise customers. This strategic optimization, along with offering discounts to AQuity customers for model transformation, had a dampening effect on revenue growth. However, the legacy IKS business continued its robust growth, and cross-sell traction within the AQuity base began to materialize in Q3, contributing to the overall 16% YoY revenue growth.

Key Deal Wins and Strategic Partnerships

IKS secured three significant deals in Q3 FY25. A 15-year, full platform deal with Palomar Health, a $1 billion health system, includes a $16.5 million upfront guarantee for Palomar and a gain-share arrangement for IKS. A strategic partnership with Radiology Partners, the largest radiology group in the US, aims to create a virtual radiology assistant model with a potential value creation of $600-700 million annually. Additionally, a relationship with Western Washington Medical Group is maturing beyond initial revenue cycle services.

AI Strategy and Product Innovation

IKS is advancing its AI strategy from cognitive RPA to GenAI-embedded automation, with 7-8 use cases across its 16 features. The company launched 'Scribble Now,' a fully autonomous GenAI and NLP-enabled clinical documentation suite, offering a comprehensive solution including Scribble Transcribe, Live, Pro, and Swift. This innovation is expected to drive significant productivity enhancements (20-35%, up to 70-85% in clinical documentation) and is supported by a new GenAI center of excellence in the US.

Capital Allocation and Debt Management

The company demonstrated strong cash generation, with operating cash flow at ₹154 crores and free cash flow at ₹109.5 crores. This enabled a significant reduction in net debt from ₹850 crores in FY24 to ₹503 crores (business as usual) by Q3 FY25. Management aims to become debt-free sometime next fiscal year, though potential tuck-in tech acquisitions or innovative customer arrangements could influence this timeline. The Palomar deal involved an upfront guarantee of ₹139 crores ($16.5 million) as an exceptional item.

Outlook and Growth Drivers

IKS expects to continue growing significantly faster than the 12% outsourced TAM growth rate, with full effects of Q3 deal ramps expected in Q4 FY25 and Q1 FY26. The company anticipates reaching early to mid-30s consolidated EBITDA margins within the next 18-24 months, potentially faster than initially projected. The long-term strategy focuses on cross-selling the full platform to its 500-odd large enterprise customers, representing 18% of the US physician market, providing a multi-decadal growth runway.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Information Technology earnings calls